Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TBHQ (tert-Butylhydroquinone) 是一种抗氧化剂,可通过对氧化还原敏感的转录因子 Nrf2 诱导抗氧化反应。它也是一种ERK 激活剂,逆转 Dehydrocorydaline 对黑素瘤细胞增殖的抑制作用。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
500 mg | ¥ 331 | 现货 | ||
1 g | ¥ 415 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 365 | 现货 |
产品描述 | TBHQ (tert-Butylhydroquinone) is an antioxidant that induces an antioxidant response through the redox-sensitive transcription factor Nrf2. |
体外活性 | HeLa cells treated with tBHQ showed preferential oxidation of mitochondrial thioredoxin-2 (Trx2), while cellular glutathione and cytosolic thioredoxin-1 were not affected. With tBHQ treatments, Trx2 overexpression suppressed Nrf2 accumulation and activity [1]. Pretreatment of Jurkat T cells with tBHQ, prior to activation with anti-CD3/anti-CD28, diminished the production of interleukin-2 (IL-2) at both the transcript and protein levels. Similarly, the expression of CD25 also diminished, albeit to a lesser degree than IL-2, after pretreatment with tBHQ [2]. |
体内活性 | TBHQ treatment prevented left ventricular dilatation and cardiac dysfunction induced by TAC and decreased the prevalence of myocardial apoptosis. TBHQ-induced Akt activation was accompanied by increased phosphorylation of Bad, glycogen synthase kinase-3β (GSK-3β) and mammalian target of rapamycin (mTOR). Blockade of the Akt pathway in vivo accelerated cardiac dysfunction, and abrogated the protective effects of TBHQ. TBHQ also reduced the reactive aldehyde production and protein carbonylation in stressed myocardium [3]. |
细胞实验 | Jurkat T cells were cultured in 96-well plates (1×10^5 cells/well) and treated as described, and cell supernatants were harvested 24h after activation with anti-CD3/anti-CD28. IL-2 was quantified from cell supernatants by the use of a commercially available kit per the manufacturer's protocol. Relative light intensity was quantified at 450nm by Bio-Tek μQuant microplate reader. The IL-2 concentrations of each sample were then calculated using a line ar standard curve on Microsoft Excel [2]. |
动物实验 | TBHQ powder was directly mixed with the animal food powder at a ratio of 1% (w/w) as described previously. The efficacy of this protocol for TBHQ treatment in vivo has also been validated by other groups. TBHQ treatment was continued for 4 weeks after the TAC surgery [3]. |
别名 | tert-Butylhydroquinone, 特丁基对苯二酚, 叔丁基氢醌 |
分子量 | 166.22 |
分子式 | C10H14O2 |
CAS No. | 1948-33-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 30 mg/mL (180.48 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 6.0161 mL | 30.0806 mL | 60.1612 mL | 150.4031 mL |
5 mM | 1.2032 mL | 6.0161 mL | 12.0322 mL | 30.0806 mL | |
10 mM | 0.6016 mL | 3.0081 mL | 6.0161 mL | 15.0403 mL | |
20 mM | 0.3008 mL | 1.504 mL | 3.0081 mL | 7.5202 mL | |
50 mM | 0.1203 mL | 0.6016 mL | 1.2032 mL | 3.0081 mL | |
100 mM | 0.0602 mL | 0.3008 mL | 0.6016 mL | 1.504 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
TBHQ 1948-33-0 Apoptosis Autophagy Immunology/Inflammation MAPK Others ERK Ferroptosis Nrf2 Keap1-Nrf2 inhibit tert-Butylhydroquinone 特丁基对苯二酚 叔丁基氢醌 Extracellular signal regulated kinases Inhibitor inhibitor